Generate a tailored SOP for Dr. Michelle Haber. Improve your application with a focused, well-structured draft.
Michelle Haber is an internationally recognized leader in childhood cancer research, particularly in neuroblastoma and high-risk leukemia. She is the Executive Director of the Children’s Cancer Institute and leads the Experimental Therapeutics Group. Her research focuses on drug resistance and the development of novel therapeutics for aggressive pediatric cancers. Professor Haber has pioneered several key programs and has contributed to the establishment of the ZERO Childhood Cancer initiative, which personalizes treatment based on genetic and biological tumor characteristics. Her team is actively involved in clinical trials that seek to enhance the effectiveness of immunotherapeutic approaches and targeted therapies. The goal of her ongoing research is to improve survival rates for children with high-risk cancers by identifying and validating novel drug targets, and implementing innovative combination therapies. She has received numerous awards for her contributions to cancer research and has published extensively in the field. Her work in developing new methods for the diagnosis and treatment of childhood cancer aims to change the landscape of pediatric oncology in Australia and beyond.
Children’s Cancer Institute • Randwick, Australia
Leading research and clinical programs for childhood cancer treatment.
Includes Business Intelligence, Enterprise Systems, and Cybersecurity Management streams.